Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
GIANTCODE Aktie jetzt für 0€ handeln |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
JANUX THERAPEUTICS | 62,36 | 0,00 % | Janux Therapeutics notches fresh record after $350 million equity raise | ||
BEAM THERAPEUTICS | 30,200 | 0,00 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,460 | 0,00 % | Recursion Pharmaceuticals, Inc.: Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability | REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 50,65 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
CG ONCOLOGY | 33,700 | 0,00 % | CG Oncology Inc.: CG Oncology Announces Proposed Public Offering | ||
QIAGEN | 43,975 | +0,62 % | Biotech Report: Evotec und Qiagen behauptet; US-Sektor legt zu | (shareribs.com) Frankfurt / New York 04.12.2024 - Biotech-Aktien zeigten sich im deutschen Handel überwiegend leichter. Unter anderem gaben 4SC und Vita34 nach. Für Evotec ging es leicht nach oben.... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 8,930 | 0,00 % | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen | |
ARS PHARMACEUTICALS | 12,950 | 0,00 % | ARS Pharmaceuticals, Inc. - 10-Q/A, Quarterly Report | ||
ARCELLX | 82,25 | 0,00 % | Safety Stands Out in Arcellx Cell Therapy's ASH Data, But Don't Overlook Manufacturing Advantages | ||
ADMA BIOLOGICS | 19,210 | 0,00 % | ADMA Stock Falls 19% From Its 52-Week High: Should You Buy the Dip? | ||
ANNEXON | 4,870 | 0,00 % | Annexon Biosciences: Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting | ||
EVOTEC | 8,940 | +1,48 % | INDEX-MONITOR: JPMorgan erwartet Evotec zurück im MDax - Dax unverändert | NEW YORK (dpa-AFX) - Zur Index-Überprüfung der Deutschen Börse an diesem Mittwochabend erwartet die US-Bank JPMorgan Kontinuität im Leitindex Dax . Im MDax DE0008467416>, dem Index für mittelgroße... ► Artikel lesen | |
QUANTUM-SI | 2,255 | 0,00 % | Quantum-Si Inc - 8-K, Current Report | ||
METAGENOMI | 4,160 | 0,00 % | Metagenomi, Inc.: Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting | ||
BIONTECH | 113,20 | +1,80 % | BioNTech, Medigene und Bayer: Deutsche Biotech-Unternehmen revolutionieren die Krebstherapie | In der Onkologie stehen spannende neue Entwicklungen an: BioNTech wandelt sich vom Covid-19-Impfstoffhersteller zum Krebsmedikamenten-Spezialisten. Mit der Übernahme des chinesischen Unternehmens Biotheus... ► Artikel lesen |